Article information
Abstract
Objectives
To determine the prevalence of class A extended spectrum β-lactamases (ESBL)-producing Escherichia coli and Klebsiella spp., and to investigate clonality among ESBL-producing isolates of nosocomial and community infections. Methods: The study involved 354 nosocomial infections samples and 992 community infections samples, obtained between 2003 and 2006 at Caxias do Sul, RS. The detection of ESBL was performed by the disk-diffusion test. Presence of blaCTX-M, blaSHV and blaTEM β-lactamase genes was evaluated by PCR, and genomic typing was determined by pulsed-field gel electrophoresis analysis. Results: Higher frequency of ESBL-producing isolates were detected among nosocomial samples of E. coli (6.7%) and Klebsiella (43.7%), than those obtained from community infections (0.4% and 2.6%). blaTEM and blaCTX were the most prevalent ESBL gene families in both E. coli and Klebsiella isolates. Different pulsotypes were obtained among ESBL-producing E. coli and 11 clones for Klebsiella spp., which occurred over the years and in different hospital wards. Among ESBL-producing K. pneumoniae, 74.3% transferred ESBL genes by conjugation and exhibited concomitant decreased aminoglycosides susceptibility. Conclusion: ESBL-producing E. coli, and especially K. pneumoniae are essentially a nosocomial problem, and their dissemination to the community is relatively limited. The great genetic variability observed among ESBL-producing bacteria indicates polyclonal spread and high transference of ESBL genes between bacteria in the hospital environment. This information is of paramount importance for nosocomial infection control.
Keywords:
β-lactamases
polymerase chain reaction
bacterial typing techniques
Full text is only aviable in PDF
References
[1]
D.L. Paterson, R.A. Bonomo.
Extended-spectrum β-lactamases: a clinical update.
Clin Microbiol Rev, 18 (2005), pp. 657-686
[2]
K. Bush, G.A. Jacoby, A.A. Medeiros.
A functional classification scheme for β-lactamases and its correlation with molecular structure.
Antimicrob Agents Chemothey, 39 (1995), pp. 1211-1233
[3]
C.G. Giske, A.S. Sundsfjord, G. Kahlmeter, et al.
Redefining extended- spectrum β-lactamase: balancing science and clinical need.
J Antimicrob Chemother, 63 (2009), pp. 1-4
[4]
G.A. Jacoby, K.E. Walsh, V.J. Walker.
Identification of extendedspectrum, AmpC, and carbapenem-hydrolyzing β-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests.
J Clin Microbiol, 44 (2006), pp. 1971-1976
[5]
A. Mena, V. Plasencia, L. García, et al.
Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development.
J Clin Microbiob, 44 (2006), pp. 2831-2837
[6]
J.J. Rahal.
The role of carbapenems in initial therapy for serious Gram-negative infectious.
Critical Care, 12 (2008), pp. 2-7
[7]
L. Poirel, J.W. Decousser, P. Nordmann.
Insertion sequence ISEcp1B is involved in expression and mobilization of the blaCTX-M β-lactamase gene.
Antimicrob Agents Chemother, 47 (2003), pp. 2938-2945
[8]
E. Machado, R. Cantón, F. Baquero, et al.
Integron content of extended-spectrum-β-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain.
Antimicrob Agents Chemother, 49 (2005), pp. 1823-1829
[9]
T.G. Slama.
Gram-negative antibiotic resistance: there is a price to pay.
Critical Care, 12 (2008), pp. S4
[10]
D.L. Paterson, W.-C. Ko, A. Gottberg, Von, et al.
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections.
Ann Intern Med, 140 (2004), pp. 26-32
[11]
D.O. Garcia, Y. Doi, D. Szabo, et al.
Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum β-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil.
Antimicrob Agents Chemother, 52 (2008), pp. 1790-1793
[12]
H. Knothe, P. Shah, V. Kramery, et al.
Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.
Infection, 11 (1983), pp. 315-317
[13]
P.A. Bradford.
Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
Clin Microbiol Rev, 14 (2001), pp. 933-951
[14]
D.L. Paterson, K.M. Hujer, A.M. Hujer, et al.
Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases.
Antimicrob Agents Chemother, 47 (2003), pp. 3554-3560
[15]
J. Rodriguez-Baño, M.D. Navarro, L. Romero, et al.
Epidemiology and clinical features of infections caused by extended- spectrum beta-lactamase-producing Escherichia coli in non-hospitalized patients.
J Clin Microbiol, 42 (2004), pp. 1089-1094
[16]
J. Oteo, C. Navarro, E. Cercenado, et al.
Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities and hospital institutions.
J Clin Microbiol, 44 (2006), pp. 2359-2366
[17]
N. Mendonça, J. Leitão, V. Manageiro, et al.
Antimicrobial Resistance Surveillance Program in Portugal; Caniça, M. Spread of extended-spectrum β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Antimicrob Agents Chemother, 51 (2007), pp. 1946-1955
[18]
J.S. Garner, W.R. Jarvis, T.G. Emori, et al.
CDC definitions isolated for nosocomial infections.
Am J Infect Control, 16 (1988), pp. 128-140
[19]
J. Rodriguez-Baño, M.D. Navarro, L. Romero, et al.
Epidemiology and clinical features of infections caused by extendedspectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.
J Clin Microbiol, 42 (2004), pp. 1089-1094
[20]
Clinical Laboratory Standards Institute (CLSI).
Performance standards for antimicrobial disk susceptibility testing. Approved standard M2-A10.
Clinical Laboratory Standards Institute, (2007),
[21]
Centers for Disease Control and Prevention. One-Day (24-28 h) Standardized Laboratory Protocol for Molecular Subtyping of Escherichia coli O157:H7, non-typhoidal Salmonella serotypes, and Shigella sonnei by Pulsed Field Gel Electrophoresis. In: PulseNet PFGE Manual http://www.cdc.gov/PulseNet/protocols/ecoli_salmonella_shigella_protocols.pdf.
[22]
F. Tenover, R. Arbeit, R. Goering, et al.
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.
J Clin Microbiol, 33 (1995), pp. 2233-2239
[23]
T.M. Coque, A. Liver, J.C. Pérez-Dias, et al.
Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum β-lactamase are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000).
Antimicrob Agents Chemother, 46 (2002), pp. 500-510
[24]
P.L. Winokur, R. Canton, J.M. Casellas, et al.
Variations in the prevalence of strains expressing an extended-spectrum β-lactamases phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.
Clin Infec Dis, 32 (2001), pp. 94-103
[25]
H.S. Sader, A.C. Gales, M.A. Pfaller, et al.
Pathogens frequency and resistance patterns in Brazilian hospitals: summary of results from three years of SENTRY antimicrobial surveillance program.
Braz J Infect Dis, 59 (2001), pp. 200-214
[26]
L.A. Minarini, A.C. Gales, I.C. Palazzo, et al.
Prevalence of community- occurring extended spectrum β-lactamase-producing Enterobacteriaceae in Brazil.
Curr Microbiol, 54 (2007), pp. 335-341
[27]
M.H. Nicolas-Chanoine, J. Blanco, V. Leflon-Guibout, et al.
Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15.
J Antimicrob Chemother, 61 (2008), pp. 273-281
[28]
L. Romero, L. López, L. Rodrigues-Baño, et al.
Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases.
Clin Microbiol Infect, 11 (2005), pp. 625-631
[29]
R. Canton, T.M. Coque.
The CTX-M β-lactamase pandemic.
Curr Opin Microbiol, (2006), pp. 466-475
[30]
J.S. Lewis, M. Herrera, B. Wickers, et al.
First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Antimicrob Agents Chemother, 51 (2007), pp. 4015-4021
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
